Altmetric

Biology of advanced uveal melanoma and next steps for clinical therapeutics

File Description SizeFormat 
nihms621657.pdfAccepted version307.07 kBAdobe PDFView/Open
Title: Biology of advanced uveal melanoma and next steps for clinical therapeutics
Authors: Luke, JJ
Triozzi, PL
McKenna, KC
Van Meir, EG
Gershenwald, JE
Bastian, BC
Gutkind, JS
Bowcock, AM
Streicher, HZ
Patel, PM
Sato, T
Sossman, JA
Sznol, M
Welch, J
Thurin, M
Selig, S
Flaherty, KT
Carvajal, RD
Item Type: Journal Article
Abstract: Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes. Patients diagnosed with a primary uveal melanoma can be stratified for risk of metastasis by cytogenetics or gene expression profiling, with approximately half of patients developing metastatic disease, predominately hepatic in location, over a 15-yr period. Historically, no systemic therapy has been associated with a clear clinical benefit for patients with advanced disease, and median survival remains poor. Here, as a joint effort between the Melanoma Research Foundation's ocular melanoma initiative, CURE OM and the National Cancer Institute, the current understanding of the molecular and immunobiology of uveal melanoma is reviewed, and on-going laboratory research into the disease is highlighted. Finally, recent investigations relevant to clinical management via targeted and immunotherpies are reviewed, and next steps in the development of clinical therapeutics are discussed.
Issue Date: 1-Sep-2014
Date of Acceptance: 5-Aug-2014
URI: http://hdl.handle.net/10044/1/40223
DOI: http://dx.doi.org/10.1111/pcmr.12304
ISSN: 1755-148X
Publisher: Wiley
Start Page: 135
End Page: 147
Journal / Book Title: Pigment Cell & Melanoma Research
Volume: 28
Issue: 2
Copyright Statement: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. This is the accepted version of the following article: Luke, J. J., Triozzi, P. L., McKenna, K. C., Van Meir, E. G., Gershenwald, J. E., Bastian, B. C., Gutkind, J. S., Bowcock, A. M., Streicher, H. Z., Patel, P. M., Sato, T., Sossman, J. A., Sznol, M., Welch, J., Thurin, M., Selig, S., Flaherty, K. T. and Carvajal, R. D. (2015), Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res, 28: 135–147, which has been published in final form at http://dx.doi.org/10.1111/pcmr.12304.
Sponsor/Funder: National Institutes of Health
Funder's Grant Number: 7R01CA161870-04
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Cell Biology
Dermatology
Ocular
Uveal
Melanoma
MEK
GNAQ
GNA11
metastasis
cancer
INDUCIBLE FACTOR PATHWAY
PROTEIN-KINASE-C
PHASE-II TRIAL
GROWTH-FACTOR RECEPTOR
IMMUNE PRIVILEGE
OCULAR MELANOMA
METASTATIC MELANOMA
ANTERIOR-CHAMBER
TUMOR-CELLS
LYMPHOCYTIC INFILTRATION
GNA11
GNAQ
MEK
Melanoma
Ocular
Uveal
cancer
metastasis
Antineoplastic Agents
Biomedical Research
Clinical Trials as Topic
Humans
Melanoma
Neoplasm Staging
Signal Transduction
Uveal Neoplasms
Humans
Melanoma
Uveal Neoplasms
Antineoplastic Agents
Neoplasm Staging
Signal Transduction
Biomedical Research
Clinical Trials as Topic
06 Biological Sciences
11 Medical And Health Sciences
Publication Status: Published
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx